Get the Stockscreener App
7.90
2.23%
-0.18
Pre-market:
8.00
0.10
+1.27%
Aura Biosciences Inc stock is traded at $7.90, with a volume of 185.73K.
It is down -2.23% in the last 24 hours and down -9.40% over the past month.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
See More
Previous Close:
$8.08
Open:
$8
24h Volume:
185.73K
Relative Volume:
0.94
Market Cap:
$394.62M
Revenue:
-
Net Income/Loss:
$-76.41M
P/E Ratio:
-4.1146
EPS:
-1.92
Net Cash Flow:
$-64.56M
1W Performance:
-4.36%
1M Performance:
-9.40%
6M Performance:
+5.33%
1Y Performance:
-11.73%
1-Day Range:
$7.87
$8.06
1-Week Range:
$7.87
$8.60
52-Week Range:
$6.63
$12.38
Aura Biosciences Inc Stock (AURA) Company Profile
Name
Aura Biosciences Inc
Sector
Industry
Phone
(617)500-8864
Address
80 GUEST STREET, BOSTON
Compare AURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
7.90 | 394.62M | 0 | -76.41M | -64.56M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.11 | 106.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.59 | 80.61B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
649.26 | 38.82B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.55 | 31.03B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.15 | 29.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-24 | Initiated | H.C. Wainwright | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jul-19-22 | Initiated | JMP Securities | Mkt Outperform |
Aura Biosciences Inc Stock (AURA) Latest News
Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews
Aura Biosciences, Inc. (NASDAQ:AURA) Receives $23.00 Consensus Price Target from Brokerages - Defense World
Rush Street Interactive, Inc. (NYSE:RSI) Receives $12.43 Consensus PT from Analysts - Defense World
Talen Energy Corporation (NASDAQ:TLN) Receives $222.40 Average Target Price from Analysts - Defense World
Brokerages Set Innovative Industrial Properties, Inc. (NYSE:IIPR) Price Target at $104.50 - Defense World
Long Focus Capital Management, LLC Increases Stake in Aura Biosc - GuruFocus.com
Barclays PLC Buys 43,897 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Why Check-Cap Shares Are Trading Higher By Over 52%; Here Are 20 Stocks Moving Premarket - Benzinga
(AURA) Trading Advice - Stock Traders Daily
Geode Capital Management LLC Raises Stock Position in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Aura Biosciences, Inc. (NASDAQ:AURA) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
State Street Corp Increases Stake in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
AB Volvo (publ) (OTCMKTS:VOLVF) Stock Price Up 0.3% – Still a Buy? - Defense World
How to Take Advantage of moves in (AURA) - Stock Traders Daily
Franklin Resources Inc. Has $15.57 Million Holdings in Aura Biosciences, Inc. (NASDAQ:AURA) - MarketBeat
Wellington Management Group LLP Takes $1.04 Million Position in Aura Biosciences, Inc. (NASDAQ:AURA) - MarketBeat
Aura Biosciences, Inc. (NASDAQ:AURA) Holdings Lifted by Charles Schwab Investment Management Inc. - Defense World
Aura Biosciences, Inc. (NASDAQ:AURA) Shares Sold by Fmr LLC - MarketBeat
Aura Biosciences, Inc. (NASDAQ:AURA) Sees Significant Growth in Short Interest - MarketBeat
How the (AURA) price action is used to our Advantage - Stock Traders Daily
Learn to Evaluate (AURA) using the Charts - Stock Traders Daily
Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference - GlobeNewswire
Cabaletta Bio to Participate in Upcoming Investor Conferences in December - The Manila Times
Aura Biosciences CEO to Present at Evercore ISI HealthCONx Conference | AURA Stock News - StockTitan
Teladoc (TDOC) Harnesses AI for Diabetes Care, Stock Rises 6.7% - MSN
When (AURA) Moves Investors should Listen - Stock Traders Daily
Aura Biosciences' chief medical officer sells $110,663 in stock By Investing.com - Investing.com Nigeria
Aura Biosciences' chief medical officer sells $110,663 in stock - Investing.com
HC Wainwright Forecasts Higher Earnings for Aura Biosciences - Defense World
HC Wainwright Has Bullish Forecast for AURA FY2024 Earnings - MarketBeat
Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update - MarketBeat
Aura Biosciences’ (AURA) Buy Rating Reiterated at HC Wainwright - Defense World
What is Leerink Partnrs’ Estimate for AURA FY2024 Earnings? - Defense World
Leerink Partnrs Has Strong Forecast for AURA FY2024 Earnings - MarketBeat
Citadel Advisors LLC Reduces Stake in Aura Biosciences Inc - GuruFocus.com
Brokerages Set Aura Biosciences, Inc. (NASDAQ:AURA) Target Price at $23.00 - Defense World
HC Wainwright Reaffirms Buy Rating for Aura Biosciences (NASDAQ:AURA) - MarketBeat
Aura Biosciences Reports Q3 Financial Results - TipRanks
Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study - MSN
Aura Biosciences : Reports Third Quarter 2024 Financial Results and Business Highlights Form 8 K - Marketscreener.com
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire
Aura Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Rating of "Buy" from Analysts - MarketBeat
(AURA) Investment Analysis - Stock Traders Daily
Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema - GlobeNewswire
One Aura Biosciences Insider Raised Stake By 232% In Previous Year - Yahoo Finance
Short Interest in Aura Biosciences, Inc. (NASDAQ:AURA) Decreases By 8.7% - MarketBeat
Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells $98,808.00 in Stock - MarketBeat
Aura Biosciences VP sells shares worth $5,938 By Investing.com - Investing.com Australia
Aura Biosciences CEO Elisabet de los Pinos sells $98,787 in stock By Investing.com - Investing.com South Africa
Aura Biosciences CEO Elisabet de los Pinos sells $98,787 in stock - Investing.com
Aura Biosciences Inc Stock (AURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):